Tempus AI (NASDAQ:TEM) CAO Sells $171,363.10 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 2,902 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $171,363.10. Following the completion of the sale, the chief accounting officer owned 41,159 shares of the company’s stock, valued at approximately $2,430,438.95. This represents a 6.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Tempus AI Stock Down 2.7%

NASDAQ TEM traded down $1.59 during midday trading on Friday, hitting $58.37. 7,883,470 shares of the company traded hands, compared to its average volume of 5,746,147. The company’s 50-day simple moving average is $62.60 and its 200-day simple moving average is $73.38. Tempus AI, Inc. has a 52 week low of $36.22 and a 52 week high of $104.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The company has a market cap of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Robert W. Baird began coverage on Tempus AI in a report on Tuesday. They issued an “outperform” rating and a $59.00 price target for the company. Piper Sandler lowered their price objective on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. BTIG Research upped their price target on Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. HC Wainwright dropped their target price on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Morgan Stanley increased their price objective on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Eight investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $85.92.

Institutional Trading of Tempus AI

Large investors have recently modified their holdings of the stock. Cranbrook Wealth Management LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at $25,000. JPL Wealth Management LLC purchased a new position in shares of Tempus AI during the third quarter worth about $26,000. GAMMA Investing LLC purchased a new position in Tempus AI during the 3rd quarter worth $28,000. Allworth Financial LP increased its holdings in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Tempus AI during the 4th quarter worth $27,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.